Investigational drug · Phase 3
Surabgene Lomparvovec
Also called: ABBV-RGX-314
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Retinopathy, Neovascular Age-related Macular Degeneration.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "Surabgene Lomparvovec"
First trial start
2025
Nov 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Surabgene Lomparvovec", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Retinopathy
- Neovascular Age-related Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Surabgene Lomparvovec" as an intervention, largest first.
- Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT05407636 · 735 participants · Start Jan 13, 2022 · Primary completion Oct 2026
Drug: Aflibercept (EYLEA®) · For: AMD; nAMD; Wet Age-related Macular Degeneration and 3 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Bakersfield, California · 181 sites in all
- Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT04704921 · 671 participants · Start Dec 29, 2020 · Primary completion Dec 2026
Drug: Ranibizumab (LUCENTIS®) · For: AMD; nAMD; Wet Age-related Macular Degeneration and 6 more
Sites: Phoenix, Arizona; Sun City, Arizona; Little Rock, Arkansas · 89 sites in all
- Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular EdemaPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07592273 · 576 participants (planned) · Start Jun 1, 2026 · Primary completion Jun 2028
Drug: Surabgene Lomparvovec; Sham and 2 more · For: Diabetic Retinopathy
Sites: Mesa, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 40 sites in all
AbbVieAbbVie (ABBV)
NCT07007065 · 561 participants (planned) · Start Nov 5, 2025 · Primary completion Mar 2033
Drug: Surabgene Lomparvovec (ABBV-RGX-314); Ranibizumab Control · For: Neovascular Age-related Macular Degeneration
Sites: Mesa, Arizona; Sun City, Arizona; Campbell, California · 138 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Emerging solutions for neovascular age-related macular degeneration.
Franco JJ, Wubben TJ · Curr Opin Ophthalmol 2026
- Emerging drugs for diabetic retinopathy: an overview of therapeutic innovation.
Castellana E, Chiappetta MR · Ther Adv Ophthalmol 2026
- Computational Fluid Dynamics Modeling of Intravitreal Ranibizumab Bolus Versus Subretinal ABBV-RGX-314 Transgene Product in Human Eyes.
Park J, Kazemi M, Tamhane M, et al. · Transl Vis Sci Technol 2025
- Beyond the injection: delivery systems reshaping retinal disease management.
Rowe LW, Akotoye C, Harris A, et al. · Expert Opin Pharmacother 2025
- Gene Therapy in Diabetic Retinopathy and Diabetic Macular Edema: An Update.
Odio-Herrera M, Orozco-Loaiza G, Wu L · J Clin Med 2025
- Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond.
Rowe LW, Ciulla TA · Genes (Basel) 2024
Also in development for Diabetic Retinopathy
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- TarcocimabTarcocimab tedromer, KSI-301Phase 32 trials
Kodiak Sciences Inc · Wet Age-related Macular Degeneration, Diabetic Retinopathy
- PER-001 Intravitreal ImplantPhase 22 trials
Perfuse Therapeutics, Inc. · Diabetic Retinopathy, Open-angle Glaucoma
- PER-001 Intravitreal Implant - ShamPhase 22 trials
Perfuse Therapeutics, Inc. · Diabetic Retinopathy, Open-angle Glaucoma
- BI 764524Phase 21 trial
Boehringer Ingelheim · Diabetic Retinopathy
- INV-102Phase 21 trial
Invirsa, Inc. · Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy
- VX-01Phase 21 trial
Vantage Biosciences Ltd · Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.